489 related articles for article (PubMed ID: 15589573)
1. Role of pegylated liposomal doxorubicin in ovarian cancer.
Thigpen JT; Aghajanian CA; Alberts DS; Campos SM; Gordon AN; Markman M; McMeekin DS; Monk BJ; Rose PG
Gynecol Oncol; 2005 Jan; 96(1):10-8. PubMed ID: 15589573
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
5. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
6. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
10. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
Pérez-López ME; Curiel T; Gómez JG; Jorge M
Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
[TBL] [Abstract][Full Text] [Related]
14. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
16. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
17. Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Uyar D; Kulp B; Peterson G; Zanotti K; Markman M; Belinson J
Gynecol Oncol; 2004 Jul; 94(1):147-51. PubMed ID: 15262133
[TBL] [Abstract][Full Text] [Related]
18. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
Rakowski JA; Ahmad S; Holloway RW
Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
[TBL] [Abstract][Full Text] [Related]
19. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
20. Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
DiSilvestro PA; Fisher M; Pearl ML; Buhl A; Chalas E; Valea FA
Gynecol Obstet Invest; 2007; 63(1):1-6. PubMed ID: 16809933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]